Skip to main content
SpringerLink
Log in

Betahistine

A Retrospective Synopsis of Safety Data

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Betahistine is a structural analogue of histamine that is prescribed for the treatment of vestibular disorders such as Ménière’s disease and the symptomatic treatment of vertigo. It is estimated from sales information that >130 million patients have been exposed to the drug since its registration in 1968. In this review we analyse the safety profile of betahistine based on data obtained during >35 years of worldwide postmarketing surveillance.

Until 31 December 2005, 554 adverse drug reaction (ADR) reports with 994 individual signs and symptoms were received by the marketing authorisation holder from worldwide sources and were reviewed and evaluated. Signs and symptoms of cutaneous hypersensitivity reactions during betahistine therapy were the most frequently reported complaints. They consisted of usually mild and self-limiting rash, pruritus and urticaria, and all symptoms were reversible after drug discontinuation. Betahistine was reported to be involved in one anaphylactoid reaction and one case of Stevens-Johnson syndrome. Anaphylactic reactions with fatal outcome were not reported.

The reports that describe gastrointestinal complaints mostly concern nausea and vomiting or unspecific abdominal pain. These were typically non-serious complaints. Hepatobiliary involvement was reported 25 times, including increases in alkaline phosphatase, γ-glutamyltransferase, and alanine and aspartate aminotransferase levels. None of the patients concerned developed severe liver failure or died. ADRs related to the nervous system predominantly reveal heterogeneous events that are not suggestive of a specific adverse reaction profile for betahistine. A clinical intolerance to betahistine that gave rise to asthma or bronchospasm was only reported in eight ADRs. A total of three cases of neoplasm have been reported. One case concerned a male patient of unknown age who experienced weight loss, insomnia, impatience and irritability soon after the start of betahistine therapy. An undiagnosed phaeochromocytoma was suspected. The remaining two cases were assessed as being unrelated to betahistine by the reporter. Finally, four deaths have been reported during the course of postmarketing surveillance for betahistine. The reporter assessed the causal relationship to betahistine in two as unrelated, in one as unlikely and the other as unassessable.

In summary, clinical and postmarketing studies have revealed a good safety profile of betahistine that was confirmed by the safety surveillance data presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Sheldon CH, Horton BT. Treatment of Meniere’s disease with histamine administered intravenously. Proc Staff Meet Mayo Clin 1940; 15: 17–21

    Google Scholar 

  2. Hill SJ, Ganellin CR, Timmerman H, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997; 49: 253–77

    CAS  PubMed  Google Scholar 

  3. Liu C, Ma XJ, Jiang X, et al. Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol Pharmacol 2001; 59: 420–6

    CAS  PubMed  Google Scholar 

  4. Arrang JM, Garbarg M, Quach TT, et al. Actions of betahistine at histamine receptors in the brain. Eur J Pharmacol 1985; 111: 73–84

    Article  CAS  PubMed  Google Scholar 

  5. Ganellin CR. Chemistry structure-activity relationship of drugs acting at histamine receptors. In: Ganellin CP, Parsons ME, editors. Pharmacology of histamine receptors. Bristol: Wright PSG, 1982: 10–102

    Chapter  Google Scholar 

  6. Gater PR, Webber SE, Gui GPH, et al. Some studies of the action of betahistine at H1 and H2 receptors for histamine. Agents Actions 1986; 18: 342–50

    Article  CAS  PubMed  Google Scholar 

  7. Curwain BP, Holton P, Spencer J. The effect of betahistine on gastric acid secretion and mucosal blood flow in conscious dogs. Br J Pharmacol 1972; 46: 351–4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Woodward DF, Ledgard SE. Histamine induced microvascular permeability increases in hamster skin: a response predominantly mediated by H2-receptors. Agents Actions 1986; 18: 504–7

    Article  CAS  PubMed  Google Scholar 

  9. West RE, Zweig A, Shih NY, et al. Identification of two H3-histamine receptor subtypes. Mol Pharmacol 1990; 38: 610–3

    CAS  PubMed  Google Scholar 

  10. Laurikainen EL, Miller JM, Nuttall AL. The vascular mechanism of action betahistine in the inner ear of the guinea pig. Eur Arch Otorhinolaryngol 1998; 255: 119–23

    Article  CAS  PubMed  Google Scholar 

  11. Dziadziola JK, Laurikainen EL, Rachel JD. Betahistine increases vestibular blood flow. Otolaryngol Head Neck Surg 1999; 120: 400–5

    Article  CAS  PubMed  Google Scholar 

  12. Soto E, Chávez H, Valli P, et al. Betahistine produces postsynaptic inhibition of the excitability of the primary neurons in the vestibular endorgans. Acta Otolaryngol Suppl 2001; 545: 19–24

    CAS  PubMed  Google Scholar 

  13. Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs 2001; 15(11): 853–70

    Article  CAS  PubMed  Google Scholar 

  14. Tighilet B, Trottier S, Mourre C, et al. Betahistine dihydrochloride interaction with the histaminergic system in the cat: neurochemical and molecular mechanisms. Eur J Pharmacol 2002; 20: 63–73

    Article  Google Scholar 

  15. Botta L, Mira E, Valli S, et al. Effects of betahistine and of its metabolites on vestibular sensory organs. Acta Otorhinolaryngol Ital 2001; 21(3 Suppl. 66): 24–30

    CAS  PubMed  Google Scholar 

  16. Chen XY, Zhong DF, Duan JL, et al. LC-MS-MS analysis of 2-pyridylacetic acid, a major metabolite of betahistine: application to a pharmacokinetic study in healthy volunteers. Xenobiotica 2003; 33: 1261–71

    Article  CAS  PubMed  Google Scholar 

  17. Reilly MA, Schayer RW. Further studies on histamine catabolism in vivo. Br J Pharmacol 1971; 43: 349–58

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Colletti V. Medical treatment in Meniere’s disease: avoiding vestibular neurectomy and facilitating postoperative compensation. Acta Otolaryngol 2000, Suppl. 544: 27–33

    Article  Google Scholar 

  19. Mira E, Guidetti G, Ghilardi PL, et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol 2003 Feb; 260(2): 73–7. Epub 2002 Sep 11

    PubMed  Google Scholar 

  20. Albera R, Ciuffolotti R, Di Cicco M, et al. Double-blind, randomized, multicentre study comparing the effect of betahistine and fluranizine on the Dizziness Handicap in patients with recurrent vestibular vertigo. Acta Otolaryngol 2003, 260: 73–7

    Google Scholar 

  21. Gordon CR, Shupak A. Prevention and treatment of motion sickness in children. CNS Drugs 1999, 12: 369–81

    Article  CAS  Google Scholar 

  22. Chistyakova VR. The role of betaserk in combined treatment of neurosensory hypoacusis and vestibulopathy in childhood. Bulletin of otorhinolaryngology 2004, 2: 9–12

    Google Scholar 

  23. Code of Federal Regulations. Title 21, Chapter 1. Food and Drug Administration, Department of Health and Human Services. Part 312.32. IND Safety Reports: revised 1 April 2002

  24. WHO Collaborating Centre for Drug Statistics Methodology [online]. About the ATC/DDD system. Available from URL: http://www.whocc.no/atcddd/atcsystem.html [Accessed 2006 Mar 18]

  25. Beeley L, Cunningham H, Brennan A. Betahistine and terfenadine. In: Stockley IH. Drug interactions. 5th Ed. London: Pharmaceutical Press, 2000: 779

    Google Scholar 

  26. CIOMS. Guidelines for preparing core clinical safety information on drugs. Report from CIOMS working group III. Genf WHO, 1995

  27. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol 2003; 57: 127–34

    Article  Google Scholar 

  28. Biriell C, Edwards R. Reasons for reporting adverse drug reactions: some thoughts based on an international review. Pharmacoepidemiol Drug Saf 1997; 6: 21–6

    Article  CAS  PubMed  Google Scholar 

  29. ICH Harmonised Tripartite Guideline. Clinical safety data management: definitions and standards for expedited reporting E2A [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA436.pdf [Acessed 2006 Mar 18]

  30. Davies AG, Stonier PD. Development of medicines: full development. In: Griffin JP, O’Grady J, editors. The textbook of pharmaceutical medicine. London: BMJ, 2003: 395–420

    Google Scholar 

  31. de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71–80

    Article  PubMed  PubMed Central  Google Scholar 

  32. Dendorfer A, Fitschen M, Raasch W, et al. Mechanisms of bradykynin-induced catecholamine release in pithed spontaneously hypertensive rats. Immunopharmacology 1999; 44: 99–104

    Article  CAS  PubMed  Google Scholar 

  33. Prys-Roberts C. Phaeochromocytoma: recent progress in its management. Br J Anaesth 2000; 85: 44–57

    Article  CAS  PubMed  Google Scholar 

  34. Schneider D, Kiepling B, Wieczorek M, et al. Influence of 3 antivertiginous medications on the vigilance of healthy volunteers. Int J Clin Pharmacol Ther 2003; 41: 171–81

    Article  CAS  PubMed  Google Scholar 

  35. Waggoner WC. Pharmacology and toxicology of Serc (betahistine hydrochloride). Report Unimed Inc Feb. 1970

    Google Scholar 

  36. Betts T, Harris D, Gadd E. The effect of two anti-vertigo drugs (betahistine and prochlorperazine) on driving skills. Br J Pharmacol 1991; 32: 455–8

    Article  CAS  Google Scholar 

  37. Kohno S, Nakao S, Ogawa K, et al. Possible participation of histamine H3-receptors in the regulation of anaphylactic histamine release from isolated rat peritoneal mast cells. Jpn J Pharmacol 1994; 66: 173–80

    Article  CAS  PubMed  Google Scholar 

  38. Chistyakova VR. The role of betaserk in combined treatment of neurosensory hypoacusis and vestibulopathy in childhood. Vestn Otorinolaringol 2004; 2: 9–12

    Google Scholar 

Download references

Acknowledgements

This work was sponsored by Solvay Pharmaceuticals. As this type of study is only possible with detailed insight into the safety data from the database of the company that produces the drug, Solvay Pharmaceuticals provided the data. The authors had direct access into the database. Both authors are employees of Solvay Pharmaceuticals.

Author information

Authors and Affiliations

  1. Solvay Pharmaceuticals, Hans-Böckler-Allee 20, Hannover, 30172, Germany

    Sabine Jeck-Thole & Wolfgang Wagner

Authors
  1. Sabine Jeck-Thole
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabine Jeck-Thole.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeck-Thole, S., Wagner, W. Betahistine. Drug-Safety 29, 1049–1059 (2006). https://doi.org/10.2165/00002018-200629110-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200629110-00004

Keywords

Search

Navigation